CureVac Shareholders Approve BioNTech Acquisition
ByAinvest
Wednesday, Dec 3, 2025 9:03 am ET1min read
BNTX--
CVAC--
BioNTech has achieved the minimum condition in its exchange offer for CureVac, with 184,071,410 shares representing 81.74% of CureVac's issued and outstanding shares tendered. The subsequent offering period has commenced and will expire on December 18, 2025. BioNTech will deliver ADSs or cash to tendering shareholders and initiate the post-offer reorganization. Non-tendering holders will receive ADSs or cash but will be subject to a 15% Dutch dividend withholding tax and transfer restrictions.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet